Longevity Biotech Funding: A Quarter-by-Quarter Analysis

All funding deals in the Longevity Biotech Market over the last years

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the Longevity Biotech Market.

Is longevity biotech funding actually growing?

Longevity biotech funding remains unpredictable, and the latest quarters show little evidence of steady market-wide growth.

Across the six quarters from Q2 2025 to Q3 2026, we recorded 24 financings totaling approximately $1.04 billion in disclosed capital. Deal volume moved from two transactions in Q2 2025 to six in Q2 2026, before falling back to four in Q3. Capital moved much more sharply because a few companies raised exceptionally large rounds.

The clearest example came in Q2 2026, when funding reached $560.4 million, almost four times the previous quarter's total. NewLimit's $435 million Series C accounted for most of that increase. Without rounds exceeding $50 million, capital actually slipped slightly from $46.1 million in Q1 to $45.4 million in Q2.

The earlier quarters tell a different story. Q3 and Q4 2025 saw more companies receiving smaller investments, including several first financings. That broader activity weakened during 2026 even as headline funding reached a record.

As of now, longevity biotech has demonstrated that selected companies can raise hundreds of millions of dollars. What we haven't seen is several consecutive quarters in which more startups raise more money across different stages and categories.

Quarter	Deals	Disclosed capital	Capital excluding rounds above $50M
Q2 2025	2	$206M	$0
Q3 2025	3	$45M	$45M
Q4 2025	5	$76.76M	$76.76M
Q1 2026	4	$146.1M	$46.1M
Q2 2026	6	$560.4M	$45.4M
Q3 2026	4	$3M disclosed	$3M disclosed

Why did longevity biotech funding fall in Q3 2025 even though more startups raised money?

Longevity biotech funding dropped 78.2% in Q3 2025 mainly because the exceptionally large rounds from the previous quarter disappeared.

In Q2, NewLimit raised $130 million in a Series B led by Kleiner Perkins, while Juvenescence secured $76 million. Those two transactions accounted for the entire quarter's $206 million total.

Q3 looked quite different. Three companies raised financing, compared with two in Q2, but the two disclosed amounts were just $35 million and $10 million. Foundry BioSciences also received investment involving XtalPi, although the amount was not publicly disclosed.

The median disclosed round fell from $103 million to $22.5 million. Meanwhile, two of the three Q3 financings were classified as first financings, compared with none in Q2.

We actually saw more first-time funding activity during the quarter with the lower capital total. Investors were backing smaller, earlier-stage businesses rather than concentrating their money in large development rounds.

The decline tells us more about which companies were raising money than about any sudden loss of interest in longevity biotechnology.

Was Q4 2025 the beginning of a real longevity biotech funding recovery?

Q4 2025 was the strongest quarter for broader longevity biotech deal activity, but the recovery lost momentum almost immediately afterward.

Deal count rose from three to five, while disclosed funding increased 70.6% to $76.76 million. Four of the five financings were between $5 million and $20 million, bringing the median round down to $10 million.

NewLimit raised another $45 million in October, with participation from Eli Lilly, Duke Management Company and other investors. Smaller financings also supported companies working on mitochondrial biology, gene and telomere therapies, and epigenetic approaches.

Importantly, two transactions were classified as first financings. That matched Q3 and gave the market two consecutive quarters with meaningful initial-funding activity.

For a moment, longevity biotech seemed to be developing a wider base of funded startups. Yet Q1 2026 brought fewer deals, and Q2 brought no recorded first financings at all.

Q4 remains the clearest example of funding reaching a wider group of companies, even though its total capital was relatively modest.

Why did longevity biotech funding jump again in Q1 2026?

Longevity biotech's Q1 2026 funding increase came mainly from Loyal's $100 million Series C, which pushed the market back toward larger investments in established developers.

Disclosed capital reached $146.1 million, up approximately 90% from Q4 2025, despite deal count falling from five to four.

Loyal announced its financing on February 11, 2026, to advance LOY-002, a treatment designed to extend healthy lifespan in senior dogs. The company had already completed enrollment of more than 1,300 dogs across over 70 veterinary clinics in its STAY study and was preparing for the remaining regulatory work and commercial launch.

That made Loyal's financing different from a typical discovery-stage biotech round. The company could point to a defined product, a large clinical program and a regulatory pathway toward market entry.

The quarter also included regenerative medicine activity involving Juvena Therapeutics and TECregen, alongside Genturn Life's financing in China, for which no precise amount was available.

Loyal alone contributed 68.4% of disclosed capital. Without its $100 million round, the quarter's total would have been $46.1 million, below Q4 2025.

The renewed growth depended heavily on one company's progress toward commercialization.

Was the Q2 2026 longevity biotech boom basically just NewLimit?

NewLimit was responsible for most of the Q2 2026 longevity biotech funding boom, although Life Biosciences added another major investment tied to clinical development.

On June 2, NewLimit announced a $435 million Series C led by Founders Fund, with participation from Thrive Capital, Greenoaks, Quiet Capital and returning investors. The company said it intended to bring its first epigenetic reprogramming medicine into human trials in 2027.

That announcement followed progress developing a prototype medicine intended to restore youthful function in aged human liver cells.

Life Biosciences had already raised $80 million in April to support the Phase 1 trial of ER-100, a therapy for optic neuropathies. On June 9, the company announced that its first clinical-trial participant had been dosed.

Together, these two financings represented $515 million, or 91.9% of the quarter's $560.4 million total.

The remaining four transactions contributed $45.4 million. Their combined amount was almost identical to the smaller-round funding recorded during Q1.

Q2 was an exceptional financing quarter for cellular reprogramming developers approaching clinical milestones. The improvement in funding conditions for other longevity startups was far less convincing.

Are longevity biotech investors writing bigger checks now?

Typical longevity biotech financing sizes have not been growing consistently, even though the sector has recently produced some enormous rounds.

Between Q1 and Q2 2026, the average disclosed financing increased from $48.7 million to $93.4 million. Over the same period, the median fell from $33.5 million to $14.5 million.

That gap is revealing. A handful of very large rounds pushed the average upward, while most companies continued to raise considerably smaller amounts.

Q4 2025 had four transactions between $5 million and $20 million. Q2 2026 also had four deals in that range, alongside Life Biosciences' $80 million financing and NewLimit's $435 million round.

The middle of the market looks particularly uneven. We found relatively few sustained sequences of $20 million to $50 million rounds that would suggest a growing population of companies progressing beyond seed financing.

At the other end, Q3 2026's disclosed median dropped to $1.5 million. That number covers only two of the quarter's four transactions, making it a poor measure of typical investment size.

For now, the clearest divide is between relatively small venture rounds and occasional investments large enough to finance expensive therapeutic-development programs.

Quarter	Median disclosed round	Average disclosed round
Q2 2025	$103M	$103M
Q3 2025	$22.5M	$22.5M
Q4 2025	$10M	$15.35M
Q1 2026	$33.5M	$48.7M
Q2 2026	$14.5M	$93.4M
Q3 2026	$1.5M	$1.5M

Are new longevity biotech startups struggling to raise their first funding?

First-time longevity biotech financing remains inconsistent, and the market's biggest funding quarters have done surprisingly little to improve access for new companies.

We counted two first financings in Q3 2025 and another two in Q4. The figure then fell to one in Q1 2026, zero in Q2 and one in Q3.

Q2 2026 is particularly striking because every one of its six transactions was classified as a follow-on financing. More capital was available than in any other quarter, but none of those transactions represented a first financing under our funding-history classification.

NewLimit illustrates how heavily existing companies can influence funding totals. Its $130 million financing in May 2025, additional $45 million investment in October and $435 million Series C in June 2026 together represented $610 million.

That is roughly 59% of all disclosed capital recorded across the six-quarter period.

Meanwhile, companies entering the funded market generally received much smaller commitments, and their financing activity fluctuated considerably from quarter to quarter.

We should distinguish first financings from newly founded companies: an older startup can raise its first publicly identified round, while a young company may already have received previous investment.

Even with that limitation, large amounts of money are returning to established developers more consistently than new companies are entering the funding market.

Is cellular reprogramming becoming the biggest opportunity in longevity biotech?

Cellular reprogramming is currently the strongest longevity biotech category for attracting large financing rounds, largely because NewLimit and Life Biosciences have moved toward clinical development.

The category recorded $130 million in Q2 2025, $55 million in Q4 and $515 million in Q2 2026.

NewLimit's research focuses on restoring youthful cellular function through epigenetic reprogramming. Its work on aged human liver cells helped support a development plan toward human trials.

Life Biosciences is pursuing a related therapeutic approach through its partial epigenetic reprogramming platform. ER-100 entered Phase 1 clinical testing for optic neuropathies in 2026, giving investors a concrete example of a reprogramming therapy reaching humans.

These developments help explain why cellular reprogramming attracts such large commitments. Clinical development requires capital for manufacturing, safety testing, trial execution and regulatory work.

But category-level funding remains heavily dependent on those two companies. In Q2 2026, cellular reprogramming represented only a third of transactions while receiving almost all disclosed capital.

Financing for advanced reprogramming programs has progressed considerably. Whether that success spreads to younger companies developing similar therapies remains an open question.

Which other longevity biotech categories are starting to attract investors?

Stem cell and regenerative therapies have shown the most consistent recent deal activity outside cellular reprogramming, while gene therapies and metabolic approaches continue attracting more occasional investments.

Stem cell and regenerative medicine companies received financing in Q1, Q2 and Q3 2026. Disclosed amounts moved from $46.1 million to $10.4 million and then $2 million.

Three consecutive active quarters show that investors remain involved, although the shrinking amounts give little reason to describe the category as accelerating.

Gene and telomere therapies appeared in four of the six quarters. Funding generally stayed in the single-digit or low-double-digit millions, without producing anything comparable to the largest reprogramming rounds.

Metabolic and mitochondrial longevity followed another pattern. The category received $35 million in Q3 2025 and $5.26 million in Q4, before Loyal's financing lifted the Q1 2026 total to $100 million.

Discovery platforms remain harder to assess. In Q3 2026, EonArk reported two separate financings, but neither amount was disclosed.

The categories are developing at different speeds. Cellular reprogramming leads in capital raised, regenerative medicine has maintained recent activity, and discovery platforms still lack enough disclosed financing information to establish a reliable direction.

Category	Most relevant funding activity	What the trend suggests
Cellular reprogramming	$515M in Q2 2026	Exceptional capital concentration
Stem cell and regenerative therapies	Three consecutive active quarters in 2026	Continued interest, smaller rounds
Gene and telomere therapies	Deals in four of six quarters	Recurring but modest financing
Metabolic and mitochondrial therapies	$100M in Q1 2026	Major increase driven by Loyal
Longevity discovery platforms	EonArk's two Q3 2026 financings	Activity with undisclosed capital
Epigenetic therapies	$5.5M in Q4 2025	Limited independent funding evidence
Autophagy and proteostasis	$12M in Q2 2026	Too early to establish momentum

Are longevity biotech investors losing interest in seed-stage startups?

Seed-stage longevity biotech funding remains active, although established developers have recently captured a much larger share of investment capital.

In Q4 2025, three of the five financings were classified as seed rounds. Early-stage activity continued into 2026, with two seed financings in both Q1 and Q2.

The difference was where the money went.

Later-stage transactions accounted for approximately 91% of Q1 2026's disclosed funding and 93% in Q2. The large commitments to Loyal, NewLimit and Life Biosciences dominated the market financially, even though smaller companies continued raising seed capital.

That split reflects different development requirements. A startup beginning research may need several million dollars to build its platform and generate initial experimental results. A company preparing regulated therapeutic trials can require tens or hundreds of millions.

By Q3 2026, seed transactions represented three of the four recorded deals, reversing the previous quarter's later-stage-heavy capital mix.

Early-stage investors haven't disappeared. The weaker point is the financing pathway between seed rounds and the very large investments available to selected mature companies.

Why are older longevity biotech companies attracting so much money?

Established longevity biotech companies have attracted the largest investments because several have reached expensive clinical or regulatory development stages.

The median age of companies receiving financing increased from approximately two years in Q4 2025 to 5.5 years in Q1 2026 and eight years in Q2.

The oldest quarterly cohort coincided with the largest capital total.

NewLimit had already completed multiple financing rounds and advanced its reprogramming research before announcing its Series C. Life Biosciences was funding an ongoing clinical-development program. Loyal was preparing for regulatory approval and commercialization.

These companies had financing needs that were substantially different from those of newly established research startups.

The pattern changed again in Q3 2026, when the median company age dropped to approximately one year. Younger businesses such as EonArk, ARTAN Bio and HexemBio became more prominent in the transaction mix.

This helps explain the uneven quarterly totals. When older developers are raising capital for expensive milestones, the market's dollar volume can surge. When younger companies dominate, deal activity may continue at much lower disclosed amounts.

Why are clinical milestones becoming so important for longevity biotech funding?

Clinical and regulatory progress has become an important factor behind the largest longevity biotech rounds because investors can increasingly connect their money to specific development targets.

NewLimit's June 2026 financing followed the identification of a prototype reprogramming medicine and supported preparations for human testing.

Life Biosciences had already obtained FDA clearance for its ER-100 investigational new drug application in January 2026. Its April financing was followed by first-patient dosing in June, moving the program from preclinical research into human testing.

Loyal offers a different example. Its LOY-002 program had received FDA acceptance of important safety and preliminary effectiveness submissions, while the STAY study had completed enrollment. Its February financing supported the remaining work toward a potential veterinary product launch.

Across all three transactions, the companies had moved beyond describing what their technology might eventually achieve. They could identify major steps they intended to complete with the new capital.

There is an important distinction between the clinical validation of a particular treatment and proof that aging itself can be broadly reversed. Neither NewLimit's planned trials nor Life Biosciences' early clinical testing establishes that their medicines will ultimately succeed.

Still, these milestones give investors something concrete to evaluate: development risk, financing requirements and timelines. That helps explain the difference in round sizes between advanced therapeutic programs and companies still establishing their underlying science.

Is US longevity biotech funding pulling ahead of Europe and Asia?

US-based longevity biotech companies continue to capture most of the largest disclosed rounds, while Asian activity is becoming more visible without yet producing comparable funding totals.

North America accounted for all five financings in Q4 2025 and received $133.5 million across two deals in Q1 2026.

The geographic imbalance became particularly pronounced in Q2, when five North American transactions contributed $543.4 million. A large majority came from NewLimit.

Asia-Pacific recorded one deal in Q1 2026, one in Q2 and two in Q3. However, the latest quarter's two transactions both involved EonArk, and neither financing amount was disclosed.

Regional deal count therefore increased without demonstrating a comparable increase in the number of companies being funded or the amount invested.

Europe appeared less consistently. Juvenescence's $76 million financing in Q2 2025 was a major contribution, but subsequent European activity remained sparse.

North America's advantage is strongest among companies raising large rounds for advanced therapeutic development. We would need more consecutive quarters of disclosed European and Asian financings before concluding that investor capital is permanently shifting between regions.

Are the same investors funding longevity biotech companies again and again?

A handful of longevity biotech investors have returned across multiple rounds, but most disclosed lead investors appear only once in our six-quarter research.

Kleiner Perkins led NewLimit's $130 million Series B in May 2025 and subsequently participated in the company's much larger June 2026 Series C.

Eli Lilly invested directly in NewLimit's October 2025 financing, while Lilly Ventures appeared among investors in the June round.

Draper Associates was involved in HexemBio's Q2 2026 seed financing and appeared again in its Q3 funding activity.

These recurring relationships suggest that some investors are continuing to support companies as their research and development programs advance.

Yet the broader evidence is less conclusive. Lead-investor disclosure varied considerably, from 100% of transactions in Q1 2026 to only 50% in Q2.

Even the quarter with the largest financing total had only three transactions with identified lead investors.

We haven't found a sustained increase in the number of active lead investors. There is evidence of repeat support for specific companies, but too little consistent disclosure to establish whether competition among investors is becoming stronger or weaker.

Are pharmaceutical companies putting more money into longevity biotech now?

Pharmaceutical companies and corporate venture investors remain active in longevity biotech, particularly when investments can support drug development or create strategic research relationships.

In Q2 2025, M42 participated in Juvenescence's financing. The following quarter, XtalPi became involved with Foundry BioSciences through an investment connected to a drug-discovery collaboration.

Eli Lilly's participation in NewLimit's October 2025 financing brought a major pharmaceutical company into one of the most heavily funded cellular reprogramming programs.

Corporate participation continued in early 2026. Boehringer Ingelheim Venture Fund backed TECregen, Eli Lilly was involved with Juvena Therapeutics, and Merck Animal Health participated in financing associated with Rejuvenate Bio.

We identified two strategically backed deals in both Q1 and Q2 2026, compared with one in each of the three preceding quarters.

However, Q3 2026 had no disclosed strategic-backed transactions.

Corporate interest looks established but uneven. It also spans several stages: pharmaceutical-related investors have backed younger research businesses alongside more mature therapeutic developers.

One important caveat concerns the size of these investments. A strategic investor's participation in a $435 million financing does not mean that investor personally contributed $435 million. Round size and individual investor commitment should not be confused.

Did longevity biotech funding really collapse in Q3 2026?

Longevity biotech recorded a dramatic fall in disclosed funding during Q3 2026, but the available figures cannot tell us how much actual investment declined.

Reported capital fell from $560.4 million to $3 million, while deal count dropped from six to four.

The largest known Q3 financing was only $2 million. Another transaction disclosed $1 million, while EonArk's two reported financings had undisclosed amounts.

Half of the quarter's transactions are therefore missing from the capital calculation.

The change in the companies receiving funding is more informative. Three deals were classified as seed-stage, and the median company age fell to approximately one year.

By contrast, Q2 had been dominated financially by mature developers raising substantial follow-on capital.

There was clearly no repeat of the previous quarter's exceptional disclosed financings. However, the 99.5% fall in recorded capital substantially overstates the precision with which we can measure the underlying change.

For now, Q3 looks like a return to smaller, younger-company financing activity, with too little disclosed information to establish the full size of the contraction.

What would prove that longevity biotech funding is genuinely recovering?

A convincing longevity biotech funding recovery would involve more startups raising successive rounds over several quarters, alongside continued investment in the sector's most advanced therapeutic programs.

The first improvement we would look for is broader deal activity. Q4 2025 demonstrated that five companies could secure financing without relying on a single nine-figure transaction. Repeated quarters with that kind of participation would make the market less dependent on occasional megadeals.

The second is stronger financing between seed and large clinical-development rounds. We would want to see more companies raising $20 million to $50 million, showing that businesses are successfully progressing beyond early research funding.

Third, growth would need to reach more categories. Cellular reprogramming has already demonstrated its ability to attract substantial investment. Comparable progress among regenerative medicine, gene and telomere therapies, and longevity discovery platforms would make the recovery much more convincing.

Finally, an increase in first financings and recurring participation from lead investors would indicate that the funding market is expanding beyond companies that already have strong financial backing.

Another exceptionally large NewLimit-style financing could set a new quarterly record. The more interesting development would be dozens of younger longevity biotechnology businesses securing enough capital to reach their next scientific and commercial milestones.

What is the longevity biotech funding trend actually telling us?

Longevity biotech has become capable of financing ambitious therapeutic-development programs, but sustained funding growth across the wider market remains unproven.

The clearest lasting pattern is concentration. The largest rounds repeatedly account for most disclosed capital, and a small number of established companies have an outsized influence on the sector's quarterly results.

First-time funding has been much less consistent. Q3 and Q4 2025 offered the strongest consecutive activity among newly financed companies, whereas the record-setting Q2 2026 contained exclusively follow-on transactions.

Cellular reprogramming has attracted the largest financial commitments, supported by concrete clinical-development progress at NewLimit and Life Biosciences. Other longevity categories remain active, although none has demonstrated equally strong and recurring funding at that scale.

The market also has an uneven financing middle. Smaller seed rounds continue to appear, and selected developers can raise hundreds of millions, but we have found limited evidence of a steadily growing population securing mid-sized rounds.

Corporate and pharmaceutical investors provide an important source of support, particularly around drug-development programs. Their participation has fluctuated rather than increased consistently.

The most misleading trend remains Q2 2026's apparent funding boom. Headline capital increased nearly fourfold, while investment excluding rounds above $50 million barely changed. That difference captures the central tension in longevity biotech fundraising.

The sector is producing companies capable of attracting extraordinary investments. Its next challenge is producing enough well-financed companies across different stages and therapeutic approaches to make that success repeatable.